Abstract 5010: A versatile tool to study immune checkpoint therapeutics: Syngenic tumor mouse models in vivo

Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Checkpoint inhibitor treatment is a common therapy of various cancer types, however, clinical data indicate that patients only partially respond to this regiment due to attenuated anti-tumor immune response. Thus, it has been recognized as important to consider the immune response already during preclinical drug development in animal experiments to anticipate such clinical drawbacks. Although immune-humanized models using human leukocytes in immuno-compromised mice may provide a starting point, syngenic mice models appear to be the better method of choice, reflecting the whole spectrum of a functional immune system. Here, we report on the establishment of syngenic mouse models for breast, colon, kidney and skin cancer both for subcutaneous and orthotopic implantation. Analyzing untreated as well as checkpoint inhibitor treated mice, we will present data on tumor growth kinetics as well on the distribution of immune cells such as Treg cells, M1/M2 macrophages and M/PMN-MDSCs in tumor and spleen tissue based on multi-color flow-cytometric analysis. These data may help to select a suitable model for testing new drug candidates and define a sensitive combination therapy to support the anti-tumor immune defense in addition to checkpoint inhibitor treatment. Citation Format: Cynthia Schaefer-Obodozie, Peter Jantscheff, Sandra Moor, Steffen Hoffmann, Tihomir Saso, Christoph Schaechtele, Holger Weber. A versatile tool to study immune checkpoint therapeutics: Syngenic tumor mouse models in vivo. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5010. doi:10.1158/1538-7445.AM2015-5010